Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer

Abstract excerpt

In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy. Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to Colorectal Cancer Treatments and Studies
• Share to Lung Cancer Treatments and Mutations